Metformin use associated with decreased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Cancer, researchers from the University of Chicago in Chicago, Illinois, have found that metformin use is associated with a decreased risk of developing colorectal cancer.
Metformin is typically the first-line oral treatment for patients with type 2 diabetes mellitus. For the study, researchers sought to examine the effects of metformin on colorectal cancer incidence in a U.S. population.
Using MarketScan databases, researchers identified patients with diabetes and colorectal cancer with each case being matched with up to two controls. The mean age of participants was 57 years for cases and 55 years for controls.
Results showed that metformin use was associated with a 15% risk reduction for the development of colorectal cancer, which was reduced to 12% after adjusting for health care use.
Researchers also found that there was no significant association between metformin dose, duration of treatment, or total exposure and risk of colorectal cancer.
Metformin use is associated with a decreased risk of developing colorectal cancer.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|